

Muzaffar H Qazilbash

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8558330/publications.pdf>

Version: 2024-02-01

259
papers

5,834
citations

109321

35
h-index

95266

68
g-index

261
all docs

261
docs citations

261
times ranked

5465
citing authors

#	ARTICLE	IF	CITATIONS
1	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1770-1781.	27.0	1,024
2	Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. <i>Lancet Oncology</i> , The, 2011, 12, 1195-1203.	10.7	263
3	Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1835-1844.	2.0	227
4	Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1975-1981.	2.0	207
5	Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 589-597.	1.6	184
6	Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 177, 457-466.	2.5	158
7	Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 718-723.	2.0	150
8	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , the, 2017, 4, e431-e442.	4.6	132
9	Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of High-Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome Using Reduced-Intensity Conditioning with Fludarabine and Melphalan. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 454-462.	2.0	117
10	Hyperacute GVHD: risk factors, outcomes, and clinical implications. <i>Blood</i> , 2007, 109, 2751-2758.	1.4	98
11	Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 344-356.	2.0	90
12	PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. <i>Leukemia</i> , 2017, 31, 697-704.	7.2	90
13	Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1183-1189.	2.0	89
14	Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. <i>Cancer</i> , 2016, 122, 3316-3326.	4.1	75
15	Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012, 53, 118-122.	1.3	74
16	Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. <i>Cancer</i> , 2006, 106, 1084-1089.	4.1	69
17	Durable remission with salvage second autotransplants in patients with multiple myeloma. <i>Cancer</i> , 2012, 118, 3549-3555.	4.1	69
18	The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. <i>British Journal of Cancer</i> , 2014, 111, 628-636.	6.4	69

#	ARTICLE	IF	CITATIONS
19	Autologous Hematopoietic Stem Cell Transplantation May Reverse Renal Failure in Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 812-816.	2.0	68
20	Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e266-e275.	4.6	68
21	Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8506-8506.	1.6	63
22	Posttransplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2016, 173, 444-455.	2.5	61
23	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	2.5	56
24	The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 319-326.	0.4	55
25	Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	49
26	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. <i>Cancer</i> , 2016, 122, 2680-2688.	4.1	48
27	Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2006, 133, 533-537.	2.5	47
28	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	4.1	47
29	Vaccination with the PR1 Leukemia-Associated Antigen Can Induce Complete Remission in Patients with Myeloid Leukemia.. <i>Blood</i> , 2004, 104, 259-259.	1.4	47
30	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1914-1920.	2.0	46
31	Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2007, 39, 279-283.	2.4	41
32	Deletion of the Short Arm of Chromosome 1 (del 1p) is a Strong Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1066-1072.	2.0	40
33	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: Results of a Phase II Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1401-1407.	2.0	39
34	A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. <i>Cancer</i> , 2012, 118, 2507-2515.	4.1	39
35	Chromosome 8q24.1 c-MYC abnormality: a marker for high-risk myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 602-607.	1.3	38
36	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1265-1270.	2.0	37

#	ARTICLE	IF	CITATIONS
37	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 906-912.	2.0	35
38	Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1227-1232.	2.0	34
39	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2710-2719.	1.6	32
40	Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. <i>Blood</i> , 2021, 138, 1373-1377.	1.4	31
41	Results of a Retrospective Single Institution Analysis of Targeted Skeletal Radiotherapy with ¹⁶⁶ Holmium-DOTMP as Conditioning Regimen for Autologous Stem Cell Transplant for Patients with Multiple Myeloma. Impact on Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 543-549.	2.0	29
42	Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 687-693.	0.4	29
43	Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 472-476.	0.4	28
44	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 798-804.	2.0	28
45	Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. <i>Cancer</i> , 2016, 122, 3831-3837.	4.1	27
46	Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. <i>Blood Cancer Journal</i> , 2016, 6, e396-e396.	6.2	27
47	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	7.2	27
48	Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2012, 53, 1525-1529.	1.3	26
49	Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2159-2164.	2.0	26
50	Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. <i>American Journal of Hematology</i> , 2012, 87, 272-276.	4.1	25
51	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 285-292.	2.0	24
52	Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 601-606.	2.4	24
53	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e532-e542.	4.6	23
54	Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2005, 80, 43-45.	4.1	22

#	ARTICLE	IF	CITATIONS
55	Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2011, 46, 510-515.	2.4	22
56	Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte colony stimulating factor for peripheral blood progenitor cell mobilization. <i>American Journal of Hematology</i> , 2013, 88, 754-757.	4.1	22
57	Plasma Cell Enrichment Enhances Detection of High-Risk Cytogenomic Abnormalities by Fluorescence In Situ Hybridization and Improves Risk Stratification of Patients With Plasma Cell Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 625-631.	2.5	22
58	Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1405-1412.	2.0	22
59	Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2197-2203.	2.0	22
60	Financial toxicity in hematological malignancies: a systematic review. <i>Blood Cancer Journal</i> , 2022, 12, 74.	6.2	22
61	The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e1-e5.	0.4	21
62	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 665-671.	2.0	21
63	Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. <i>Bone Marrow Transplantation</i> , 2019, 54, 1089-1093.	2.4	20
64	High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. <i>Lancet Haematology</i> , 2017, 4, e283-e292.	4.6	19
65	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). <i>Bone Marrow Transplantation</i> , 2022, 57, 51-56.	2.4	19
66	Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). <i>Blood Cancer Journal</i> , 2022, 12, 27.	6.2	19
67	A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1453-1458.	2.0	18
68	Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. <i>European Journal of Haematology</i> , 2017, 99, 532-535.	2.2	18
69	Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 430.e1-430.e7.	1.2	18
70	Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. <i>Bone Marrow Transplantation</i> , 2021, 56, 1316-1324.	2.4	18
71	Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. <i>Bone Marrow Transplantation</i> , 2014, 49, 1036-1041.	2.4	17
72	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1607-1615.	1.3	17

#	ARTICLE	IF	CITATIONS
73	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1439-1445.	2.0	17
74	Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. <i>Blood Advances</i> , 2022, 6, 3027-3035.	5.2	17
75	Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. <i>American Journal of Hematology</i> , 2016, 91, E442-7.	4.1	16
76	Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. <i>Blood</i> , 2018, 131, 1248-1257.	1.4	16
77	Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 197-203.	2.0	16
78	Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 74.	17.0	15
79	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 961-965.	2.0	15
80	Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 226-231.	2.0	15
81	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1602-1609.	2.0	15
82	High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. <i>Leukemia and Lymphoma</i> , 2019, 60, 442-452.	1.3	15
83	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 505-514.	2.0	15
84	Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancers</i> , 2021, 13, 5888.	3.7	15
85	Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implications. <i>Experimental Hematology</i> , 2013, 41, 719-730.	0.4	14
86	Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 581-587.	2.0	14
87	Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 689-695.	1.2	14
88	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. <i>Blood</i> , 2019, 134, 2723-2723.	1.4	14
89	Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2006, 108, 315-315.	1.4	14
90	Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 815-819.	2.0	13

#	ARTICLE	IF	CITATIONS
91	HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. <i>Current Research in Translational Medicine</i> , 2019, 67, 51-55.	1.8	13
92	Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 264.e1-264.e7.	1.2	13
93	Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. <i>Haematologica</i> , 2021, 106, 3211-3214.	3.5	13
94	Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. <i>Leukemia</i> , 2015, 29, 1945-1948.	7.2	12
95	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 122-128.	0.4	12
96	A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-Hodgkin lymphomas: long term results. <i>British Journal of Haematology</i> , 2017, 178, 561-570.	2.5	12
97	Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 388-392.	2.2	12
98	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 272.e1-272.e5.	1.2	12
99	Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. <i>American Journal of Hematology</i> , 2023, 98, 140-147.	4.1	12
100	Nonmyeloablative Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S261-S265.	1.4	11
101	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. <i>Cancer</i> , 2017, 123, 3568-3575.	4.1	11
102	Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 126-135.	2.3	11
103	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥ 75 years. <i>Leukemia and Lymphoma</i> , 2019, 60, 3536-3543.	1.3	11
104	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1039-1044.	2.0	11
105	Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2020, 104, 420-426.	2.2	11
106	Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. <i>Blood Advances</i> , 2020, 4, 4834-4837.	5.2	11
107	POEMS syndrome: A multisystem clonal disorder. <i>European Journal of Haematology</i> , 2021, 106, 14-18.	2.2	11
108	Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. <i>Bone Marrow Transplantation</i> , 2021, 56, 2005-2012.	2.4	11

#	ARTICLE	IF	CITATIONS
109	Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?. World Journal of Transplantation, 2017, 7, 250-259.	1.6	11
110	Retrospective analysis of weekly intravenous immunoglobulin prophylaxis versus intravenous immunoglobulin by IgG level monitoring in hematopoietic stem cell transplant recipients. American Journal of Hematology, 2012, 87, 172-174.	4.1	10
111	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clinical Cancer Research, 2019, 25, 6781-6787.	7.0	10
112	Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy, 2021, 27, 1003.e1-1003.e13.	1.2	10
113	Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. European Journal of Haematology, 2016, 97, 342-347.	2.2	9
114	Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplantation, 2018, 53, 315-325.	2.4	9
115	A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. Blood, 2022, 139, 1289-1301.	1.4	9
116	PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia.. Blood, 2007, 110, 283-283.	1.4	9
117	Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. Blood, 2015, 126, 3155-3155.	1.4	9
118	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 83.e1-83.e9.	1.2	9
119	Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 703-713.	2.2	8
120	The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes. American Journal of Hematology, 2010, 85, 502-504.	4.1	8
121	Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms. Leukemia Research, 2014, 38, 896-900.	0.8	8
122	Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. Experimental Hematology, 2020, 81, 32-41.	0.4	8
123	Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older. Cancer, 2021, 127, 4233-4239.	4.1	8
124	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leukemia and Lymphoma, 2022, 63, 710-721.	1.3	8
125	Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma. Leukemia and Lymphoma, 2006, 47, 1360-1364.	1.3	7
126	High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplantation, 2015, 50, 668-672.	2.4	7

#	ARTICLE	IF	CITATIONS
127	Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 999-1001.	2.4	7
128	Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. <i>British Journal of Haematology</i> , 2017, 177, 567-577.	2.5	7
129	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1340-1346.	2.0	7
130	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. <i>Blood Advances</i> , 2020, 4, 1296-1306.	5.2	7
131	KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1142-1149.	2.4	7
132	High-Dose Therapy and Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Disease: Outcome Based on a Prognostic Model. <i>Acta Haematologica</i> , 2003, 110, 173-178.	1.4	6
133	Utility of a Prognostic Scoring System for Allogeneic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia. <i>Acta Haematologica</i> , 2003, 109, 119-123.	1.4	6
134	Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. <i>Transfusion</i> , 2017, 57, 1052-1057.	1.6	6
135	Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 263-268.	2.2	6
136	Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. <i>Annals of Hematology</i> , 2019, 98, 2233-2235.	1.8	6
137	Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. <i>Haematologica</i> , 2019, 104, e555-e557.	3.5	6
138	Haploidentical transplants for patients with relapse after the first allograft. <i>American Journal of Hematology</i> , 2020, 95, 1187.	4.1	6
139	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 913.e1-913.e12.	1.2	6
140	Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2005, 106, 1135-1135.	1.4	6
141	Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2270-2270.	1.4	6
142	Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 395.e1-395.e11.	1.2	6
143	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1413-1417.	2.0	5
144	Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 36-42.	0.4	5

#	ARTICLE	IF	CITATIONS
145	Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. <i>Quality of Life Research</i> , 2018, 27, 979-985.	3.1	5
146	Melphalanâ€based autologous transplant in octogenarian multiple myeloma patients. <i>American Journal of Hematology</i> , 2019, 94, E2-E5.	4.1	5
147	Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1746-1749.	2.4	5
148	Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 46-47.	1.4	5
149	Maintenance Therapy with 5-Azacytidine (5-AC) after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS): A Dose and Schedule Finding Study.. <i>Blood</i> , 2006, 108, 3668-3668.	1.4	5
150	PR1 Vaccine Elicited Immunological Response after Hematopoietic Stem Cell Transplantation Is Associated with Better Clinical Response and Event-Free Survival.. <i>Blood</i> , 2007, 110, 577-577.	1.4	5
151	A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. <i>Blood</i> , 2012, 120, 4200-4200.	1.4	5
152	Circulating Plasma Cells By Routine Complete Blood Count Identify Patients With Similar Outcome As Plasma Cell Leukemia. <i>Blood</i> , 2013, 122, 5356-5356.	1.4	5
153	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. <i>Blood</i> , 2015, 126, 854-854.	1.4	5
154	Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. <i>Bone Marrow Transplantation</i> , 2014, 49, 465-466.	2.4	4
155	A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. <i>Leukemia and Lymphoma</i> , 2018, 59, 515-518.	1.3	4
156	Longâ€term durable efficacy of autologous stem cell transplantation in POEMS syndrome. <i>American Journal of Hematology</i> , 2018, 94, E72-E74.	4.1	4
157	New Cancer Therapies: Implications for the Perioperative Period. <i>Current Anesthesiology Reports</i> , 2018, 8, 362-367.	2.0	4
158	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1077-1083.	2.0	4
159	Plasmablastic Lymphoma: 28 Patient Single Institution Experience. <i>Blood</i> , 2013, 122, 4310-4310.	1.4	4
160	Feasibility of a Smartphone-Based Health Coaching Intervention for Patient Self-Management of Nutrition in the Post-Chemotherapy Setting. <i>Blood</i> , 2016, 128, 3554-3554.	1.4	4
161	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 31-37.	2.4	4
162	Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience,. <i>Blood</i> , 2011, 118, 4118-4118.	1.4	4

#	ARTICLE	IF	CITATIONS
163	Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 1277-1284.	7.0	4
164	Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. <i>Bone Marrow Transplantation</i> , 2016, 51, 307-309.	2.4	3
165	Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1059-1063.	2.0	3
166	Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3101-3111.	1.3	3
167	Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. <i>British Journal of Haematology</i> , 2021, 192, e115-e120.	2.5	3
168	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 404.e1-404.e5.	1.2	3
169	Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. <i>Clinical Cancer Research</i> , 2021, 27, 5847-5856.	7.0	3
170	Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. <i>American Journal of Hematology</i> , 2021, 96, E455-E457.	4.1	3
171	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: A New Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2005, 106, 1159-1159.	1.4	3
172	Retrospective Comparison of Transplant Outcomes in Patients with Multiple Myeloma According to Induction Therapy with Thalidomide/Dexamethasone (TD) with or without Bortezomib (VTD).. <i>Blood</i> , 2007, 110, 948-948.	1.4	3
173	Allogeneic transplantation for myelofibrosis: Benefit of dose intensity.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7011-7011.	1.6	3
174	Donor Cell-Derived Myelodysplastic Syndrome With Ring Chromosome 7 After Allogeneic Hematopoietic Stem Cell Transplant in 2 Patients With Lymphomas as Primary Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e151-e155.	0.4	2
175	The therapeutic role of natural killer cells in multiple myeloma. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e49.	0.9	2
176	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2021, 144, 74-81.	1.4	2
177	Sequential Treatment with Reduced Intensity Allogeneic Stem Cell Transplantation and Imatinib for		

#	ARTICLE	IF	CITATIONS
181	Nonmyeloablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd. <i>Blood</i> , 2011, 118, 894-894.	1.4	2
182	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. <i>Hematological Oncology</i> , 2022, 40, 49-57.	1.7	2
183	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 295-298.	2.4	2
184	Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. <i>Blood</i> , 2021, 138, 482-482.	1.4	2
185	Phase II study of umbilical cord blood-derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 8009-8009.	1.6	2
186	Autologous Hematopoietic Stem Cell Transplantation in Light Chain Amyloidosis (AL) With Renal Involvement. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S234-S235.	2.0	1
187	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 243.e1-243.e6.	1.2	1
188	Improved outcomes with maintenance therapy after salvage autologous hematopoietic cell transplantation (AHCT) in multiple myeloma: A CIBMTR study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8022-8022.	1.6	1
189	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3090-3090.	1.4	1
190	Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2011, 118, 333-333.	1.4	1
191	EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma.. <i>Blood</i> , 2012, 120, 3094-3094.	1.4	1
192	Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 5884-5884.	1.4	1
193	Fixed-Dose Single Agent Pegfilgrastim for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma (MM).. <i>Blood</i> , 2005, 106, 2923-2923.	1.4	1
194	A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.. <i>Blood</i> , 2007, 110, 3032-3032.	1.4	1
195	Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS. <i>Blood</i> , 2008, 112, 2999-2999.	1.4	1
196	Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).. <i>Blood</i> , 2009, 114, 2310-2310.	1.4	1
197	Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 4354-4354.	1.4	1
198	Role of Serum Lactate Dehydrogenase (LDH) As a Prognostic Marker for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. <i>Blood</i> , 2012, 120, 3115-3115.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.. Blood, 2012, 120, 3129-3129.	1.4	1
200	A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. Blood, 2019, 134, 257-257.	1.4	1
201	African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. Blood, 2020, 136, 9-10.	1.4	1
202	Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 24-25.	1.4	1
203	Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 307.e1-307.e8.	1.2	1
204	Hematopoietic Cell Transplantation for Multiple Myeloma. , 0, , 845-859.		0
205	Impact of renal impairment on light chain amyloidosis outcomes after autologous hematopoietic stem cell transplantation. Annals of Translational Medicine, 2020, 8, 509-509.	1.7	0
206	Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H.. Blood, 2004, 104, 5132-5132.	1.4	0
207	Second Autologous or Allogeneic Transplantation after the Failure of First Autograft in Multiple Myeloma.. Blood, 2004, 104, 3329-3329.	1.4	0
208	The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).. Blood, 2005, 106, 1803-1803.	1.4	0
209	High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkinâ€™s Lymphoma (NHL) in Patients over 65 Years of Age.. Blood, 2006, 108, 3059-3059.	1.4	0
210	Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma.. Blood, 2006, 108, 5422-5422.	1.4	0
211	Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant.. Blood, 2006, 108, 3101-3101.	1.4	0
212	Autotransplantation in Patients with Multiple Myeloma and Concurrent Renal Failure Is Safe and Feasible and Associated with Recovery of Renal Function in > 30% of Patients.. Blood, 2007, 110, 5126-5126.	1.4	0
213	Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkinâ€™s Lymphomas (NHLs).. Blood, 2007, 110, 1900-1900.	1.4	0
214	Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation.. Blood, 2007, 110, 3002-3002.	1.4	0
215	Risk Factors for Response after Initial Therapy for Acute Graft-Versus-Host-Disease (aGVHD).. Blood, 2007, 110, 5015-5015.	1.4	0
216	Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.. Blood, 2008, 112, 1128-1128.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Rituximab Containing Autologous Stem Cell Transplantation May Be Curative in Mantle Cell Lymphoma for Patients in First Remission, but Not for Patients with Recurrent Disease.. Blood, 2008, 112, 1142-1142.	1.4	0
218	Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. Blood, 2008, 112, 3298-3298.	1.4	0
219	Outcome of Allogeneic Stem Cell Transplantation in Patients with Low Ventricular Ejection Fraction. Blood, 2008, 112, 3306-3306.	1.4	0
220	Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 4326-4326.	1.4	0
221	Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies. Blood, 2008, 112, 3297-3297.	1.4	0
222	Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. Blood, 2008, 112, 799-799.	1.4	0
223	Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).. Blood, 2009, 114, 3213-3213.	1.4	0
224	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.. Blood, 2009, 114, 2309-2309.	1.4	0
225	Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma.. Blood, 2009, 114, 1227-1227.	1.4	0
226	Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. Blood, 2010, 116, 3510-3510.	1.4	0
227	A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma,. Blood, 2011, 118, 4108-4108.	1.4	0
228	Determinants of Higher Pre-Apheresis CD34+ Count in Patients Undergoing Autologous Hematopoietic Stem Cell Mobilization. Blood, 2011, 118, 4387-4387.	1.4	0
229	A Comparative Study of the Outcome of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Standard-Risk Myeloma Treated Concurrently,. Blood, 2011, 118, 4156-4156.	1.4	0
230	Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. Blood, 2011, 118, 2006-2006.	1.4	0
231	C-MYC Rearrangement: A Marker for High-Risk Myeloma. Blood, 2012, 120, 4989-4989.	1.4	0
232	Acquired Therapy-Related Cytogenetic Clones in Patients Treated for Multiple Myeloma. Blood, 2012, 120, 4059-4059.	1.4	0
233	Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2013, 31, 7010-7010.	1.6	0
234	Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblastic Leukemia (ALL) With First Complete Remission (CR). Blood, 2013, 122, 2142-2142.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3358-3358.	1.4	0
236	Autologous stem cell transplantation in dialysis-dependent myeloma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8601-8601.	1.6	0
237	Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8538-8538.	1.6	0
238	Use of Gene Expression Profiling May Predict Clinical Outcomes in Newly Diagnosed Multiple Myeloma Patients in a Standard of Care Setting. <i>Blood</i> , 2015, 126, 5390-5390.	1.4	0
239	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. <i>Blood</i> , 2018, 132, 4607-4607.	1.4	0
240	Impact of autologous stem cell transplant in myeloma patients on renal function and overall survival.. <i>Journal of Clinical Oncology</i> , 2019, 37, e19535-e19535.	1.6	0
241	Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. <i>Blood</i> , 2019, 134, 4598-4598.	1.4	0
242	Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 1779-1779.	1.4	0
243	Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. <i>Blood</i> , 2020, 136, 11-13.	1.4	0
244	PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. <i>Blood</i> , 2020, 136, 6-7.	1.4	0
245	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 18-19.	1.4	0
246	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 22-22.	1.4	0
247	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. <i>Blood</i> , 2020, 136, 17-18.	1.4	0
248	Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. <i>Blood</i> , 2020, 136, 24-25.	1.4	0
249	Trial in Progress: A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 37-38.	1.4	0
250	Maintenance Use Is More Important Than the Choice of Bortezomib-Based Triplet Induction in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 36-37.	1.4	0
251	Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
252	Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. <i>Blood</i> , 2020, 136, 10-11.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. <i>Blood</i> , 2020, 136, 14-15.	1.4	0
254	Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 23-24.	1.4	0
255	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
256	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
257	Stability of Captisol-enabled versus propylene glycol-based melphalan at room temperature and after refrigeration. <i>American Journal of Health-System Pharmacy</i> , 2022, , .	1.0	0
258	Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8057-8057.	1.6	0
259	Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20024-e20024.	1.6	0